Discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC #GU16

Guillermo De Velasco, MD at Dana Farber discusses discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC at ASCO GU 2016 Author: 2016_Genitourinary Added: 03/03/2016
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts